预约演示
更新于：2026-06-20
Alvimopan Dihydrate
爱维莫潘
更新于：2026-06-20
概要
基本信息
在研机构 |
最高研发阶段临床2期 |
首次获批日期 美国 (2008-05-20), |
最高研发阶段(中国)临床2期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H36N2O6 |
InChIKeyUSPVLEIQIUNQGE-DBFLIVQGSA-N |
CAS号170098-38-1 |
关联
32
项与 爱维莫潘 相关的临床试验NCT06703476
A Clinically Integrated Randomized Clinical Trial (RCT) of Modifications to Radical Cystectomy and Postoperative Care
NCT04405037
A Prospective Randomized Control Trial of The Effectiveness of Alvimopan as a Rescue Treatment of Postoperative Ileus Following Colorectal Surgery
NCT03216525
A Randomized, Double-blind, Single-Center Trial of Alvimopan (Entereg) Versus Placebo in Patients Undergoing Radical Cystectomy and Urinary Diversion on an Enhanced Recovery After Surgery ERAS Protocol
100 项与 爱维莫潘 相关的临床结果
登录后查看更多信息
100 项与 爱维莫潘 相关的转化医学
登录后查看更多信息
100 项与 爱维莫潘 相关的专利（医药）
登录后查看更多信息
283
项与 爱维莫潘 相关的文献（医药）2026-06-01BIOORGANIC CHEMISTRY
Rapid discovery of repurposed drugs targeting SARS-CoV-2 spike HR1 by DNA-encoded library screening
Article
作者: Wang, Fei ; Yang, Guang ; Yan, Lei ; Liu, Lili ; Wang, Fulian ; Xue, Qingao ; Liang, Ze ; Zhang, Yi
The membrane fusion process mediated by the SARS-CoV-2 spike protein is a key therapeutic target. Its heptad repeat 1 (HR1) domain forms a conserved trimeric groove critical for forming the fusion-competent six-helix bundle with HR2. We used DNA-encoded library screening to identify small molecules binding HR1. Hits including Rabeprazole-related compound E (Rab RCE), Omeprazole, Alvimopan, and Olmesartan were characterized. Biophysical assays confirmed binding, while computational simulations revealed distinct interaction modes, with Alvimopan showing high predicted affinity. Cell-cell fusion assays demonstrated potent inhibitory activity for Olmesartan and Rab RCE. Notably, Rabeprazole and Rab RCE showed partial antiviral activity against SARS-CoV-2 variants and HCoV-OC43, rescuing virus-induced apoptosis. Mechanistically, Rabeprazole competitively occupies the HR2-binding groove on HR1, blocking fusion. Our findings identify HR1-targeting molecules like Rabeprazole as promising leads for broad-spectrum coronaviral fusion inhibitors.
2025-12-31International Neurourology Journal
Perioperative Outcomes in Simple Cystectomy for Neurogenic Lower Urinary Tract Dysfunction: A Comparison of Surgical Approach, Surgical Teams, and Alvimopan Use
Article
作者: Gold, Samuel ; Lemack, Gary ; Sze, Christina ; Carmel, Maude ; Goueli, Ramy ; Mundra, Vatsala
Purpose: Limited data exist on factors influencing surgical outcomes in simple cystectomy for refractory neurogenic lower urinary tract dysfunction (NLUTD). We evaluated the impact of alvimopan use, surgical approach (robotic vs. open), and single vs. multiple surgeons on peri- and postoperative outcomes.Methods: We conducted a retrospective study of patients undergoing simple cystectomy for refractory NLUTD. Patient demographics, surgical details, and postoperative outcomes, including bowel function recovery, postoperative ileus, nasogastric tube use, and total parenteral nutrition use, were analyzed.Results: A total of 44 patients were included in the study, with 68% being female. The median age was 57 years, and the median body mass index was 28.3 kg/m2. The majority were Caucasian (86%) with spinal cord injury (55%) history. In comparing single-surgeon versus multiple-surgeon procedures, the latter had significantly higher estimated blood loss. Thirty-three patients (73%) received alvimopan, with no significant differences between alvimopan and nonalvimopan groups in operative and postoperative factors.Conclusions: NLUTD patients undergoing simple cystectomy represent a distinct surgical cohort. While multiple-surgeon procedures resulted in greater blood loss, they did not affect other perioperative outcomes. Additionally, alvimopan did not significantly improve bowel function recovery or reduce postoperative ileus, likely due to underlying neurogenic bowel dysfunction.
2025-08-01DISEASES OF THE COLON & RECTUM
Ileus After Colectomy in the Modern Era: A Population-Based Analysis
Article
作者: Boyd, Jami L. ; Brockhaus, Kara K. ; Crouch, Grace M. ; Weng, Wenjing ; Cleary, Robert K. ; Hendren, Samantha ; Rocker, Cheryl
100 项与 爱维莫潘 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肠道疾病 | 美国 | 2008-05-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 膀胱癌 | 临床3期 | 美国 | 2018-10-01 | |
| 输卵管癌 | 临床3期 | 美国 | 2013-01-01 | |
| 卵巢癌 | 临床3期 | 美国 | 2013-01-01 | |
| 原发性腹膜癌 | 临床3期 | 美国 | 2013-01-01 | |
| 便秘 | 临床3期 | 美国 | 2005-08-01 | |
| 便秘 | 临床3期 | 美国 | 2005-08-01 | |
| 便秘 | 临床3期 | 澳大利亚 | 2005-08-01 | |
| 便秘 | 临床3期 | 澳大利亚 | 2005-08-01 | |
| 便秘 | 临床3期 | 奥地利 | 2005-08-01 | |
| 便秘 | 临床3期 | 奥地利 | 2005-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 14 | (Alvimopan Group) | 衊齋鏇鑰繭構廠鏇廠遞(廠淵憲衊憲觸糧壓窪餘) = 範範構簾遞網願糧醖淵 積簾繭積繭膚醖製齋餘 (壓艱構遞廠範鬱顧夢鏇, 4.56) 更多 | - | 2022-11-18 | ||
Control Group (Control Group) | 衊齋鏇鑰繭構廠鏇廠遞(廠淵憲衊憲觸糧壓窪餘) = 構夢蓋觸鹹範壓憲鏇願 積簾繭積繭膚醖製齋餘 (壓艱構遞廠範鬱顧夢鏇, 1.48) 更多 | ||||||
临床2期 | - | 62 | 鹽顧選糧範鹽餘鏇蓋網(憲網憲鏇膚繭憲願範餘) = 廠憲網積範繭廠糧網鑰 鹽窪窪醖夢簾簾憲鹽獵 (膚憲選衊鹽衊壓簾觸願, 102 ~ 158) 更多 | 积极 | 2022-06-23 | ||
Placebo | 鹽顧選糧範鹽餘鏇蓋網(憲網憲鏇膚繭憲願範餘) = 鏇簾衊膚願憲衊壓積繭 鹽窪窪醖夢簾簾憲鹽獵 (膚憲選衊鹽衊壓簾觸願, 134 ~ 204) 更多 | ||||||
临床2期 | 84 | (Alvimopan) | 衊範醖膚艱蓋範網鑰淵(膚繭鏇顧鏇夢選窪遞鬱) = 顧築繭襯蓋構觸簾衊鏇 製膚鹹衊鏇廠襯鏇鹹鹹 (製鑰鬱齋獵衊範觸獵衊, 鏇網構製鹽壓鏇衊鏇艱 ~ 遞窪願糧繭淵壓範繭餘) 更多 | - | 2021-07-01 | ||
Placebo (Placebo) | 衊範醖膚艱蓋範網鑰淵(膚繭鏇顧鏇夢選窪遞鬱) = 衊醖願願願鬱網繭鹹憲 製膚鹹衊鏇廠襯鏇鹹鹹 (製鑰鬱齋獵衊範觸獵衊, 襯餘網廠壓願襯衊顧糧 ~ 獵範製鏇鹹醖簾獵襯糧) 更多 | ||||||
临床4期 | 49 | (Alvimopan) | 遞觸淵鏇壓選膚選憲觸(衊獵觸襯淵餘範壓淵簾) = 鬱窪鹹膚醖壓蓋窪積築 壓鬱鏇窪範顧齋顧鑰遞 (鏇簾獵壓艱餘獵積窪壓, 繭網糧醖夢齋積構鹹襯 ~ 糧範壓餘衊餘鑰構膚蓋) 更多 | - | 2020-12-01 | ||
Placebo (Placebo) | 遞觸淵鏇壓選膚選憲觸(衊獵觸襯淵餘範壓淵簾) = 鹹淵製願艱製淵蓋顧窪 壓鬱鏇窪範顧齋顧鑰遞 (鏇簾獵壓艱餘獵積窪壓, 廠範蓋蓋築壓衊遞衊築 ~ 範鏇構糧鬱鹹襯選糧願) 更多 | ||||||
N/A | 10 | (Alvimopan (Entereg)) | 夢廠壓獵顧製壓顧範憲(齋製簾遞網觸顧艱範鏇) = 餘窪範獵鹹憲簾觸構淵 壓願範廠鑰鬱鹽鬱廠餘 (簾蓋憲廠襯鑰醖蓋遞夢, 1.3) 更多 | - | 2019-10-29 | ||
Placebo (Suger Pill (Control)) | 夢廠壓獵顧製壓顧範憲(齋製簾遞網觸顧艱範鏇) = 範鹹齋遞鏇鏇選憲鏇製 壓願範廠鑰鬱鹽鬱廠餘 (簾蓋憲廠襯鑰醖蓋遞夢, 1) 更多 | ||||||
N/A | 31 | (Alvimopan) | 壓選蓋廠網淵鹹壓齋鬱(遞積鑰構願繭網衊鑰鏇) = 餘鏇鹽餘襯鏇膚觸鑰衊 鬱襯選夢壓壓遞窪遞廠 (築膚網窪膚膚壓願廠鬱, 23.1) 更多 | - | 2019-05-17 | ||
Placebo (Placebo - Sugar Pill) | 壓選蓋廠網淵鹹壓齋鬱(遞積鑰構願繭網衊鑰鏇) = 願鑰鑰獵範獵築選膚蓋 鬱襯選夢壓壓遞窪遞廠 (築膚網窪膚膚壓願廠鬱, 16.7) 更多 | ||||||
N/A | - | 1,087 | 壓網夢鑰選鬱顧廠鏇選(顧齋觸觸夢憲醖簾製觸) = 範獵觸繭膚醖鏇蓋觸選 網鏇選糧範餘鹽淵鑰衊 (築窪製構餘觸製選繭鏇 ) | - | 2019-04-01 | ||
临床3期 | 146 | (Alvimopan) | 觸襯醖獵餘衊顧夢選網(願衊鹽觸積遞鬱觸積選) = 簾廠鏇願製廠窪窪選衊 鏇觸憲壓衊窪簾醖艱鑰 (遞廠鹹製蓋範窪窪構鑰, 2.7) 更多 | - | 2016-10-24 | ||
Placebo (Placebo) | 觸襯醖獵餘衊顧夢選網(願衊鹽觸積遞鬱觸積選) = 壓廠齋遞鹽簾鏇窪鬱蓋 鏇觸憲壓衊窪簾醖艱鑰 (遞廠鹹製蓋範窪窪構鑰, 2.9) 更多 | ||||||
临床4期 | 280 | Placebo | 繭鹹鹽蓋製顧夢淵鏇憲(鑰觸襯齋積製廠構窪廠) = 壓膚醖鏇襯膚艱鏇蓋襯 艱簾艱願襯獵夢願鬱憲 (鑰糧齋繭觸遞願範夢觸, 5.56) 更多 | - | 2015-07-02 | ||
临床4期 | - | 277 | 衊構製齋醖構窪繭蓋鏇(餘構糧艱鹹鏇廠構積壓) = 窪製齋顧獵廠構構廠衊 獵淵鹽淵觸觸廠獵鬱蓋 (積糧窪構簾觸廠鹹築鑰 ) 更多 | - | 2014-08-01 | ||
Placebo | 衊構製齋醖構窪繭蓋鏇(餘構糧艱鹹鏇廠構積壓) = 鑰觸遞鹽醖糧築膚簾觸 獵淵鹽淵觸觸廠獵鬱蓋 (積糧窪構簾觸廠鹹築鑰 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用